Novartis Starts Late Stage Trials For Afinitor In Breast Cancer
Novartis Starts Late Stage Trials For Afinitor In Breast Cancer
Novartis Starts Late Stage Trials For Afinitor In Breast Cancer
Read more on FOX Business
Categories: Metastatic Breast Cancer Tags: Afinitor, breast, cancer, Late, Novartis, Stage, starts, Trials
Longer-term Phase III data show Novartis drug Tasigna® continues to surpass Glivec® in slowing disease progression in …
Longer-term Phase III data show Novartis drug Tasigna® continues to surpass Glivec® in slowing disease progression in …
Novartis International AG / Longer-term Phase III data show Novartis drug Tasigna® continues to surpass Glivec® in slowing disease progression in patients with newly diagnosed CML Processed and transmitted by Thomson Reuters. The issuer is …
Read more on wallstreet:online AG
Categories: Breast Cancer Information Tags: Continues, Data, Disease, drug, Glivec®, Longerterm, Novartis, Phase, Progression, Show, slowing, surpass, Tasigna®
Novartis Gains FDA Approval For Gilenya™, A Novel First-Line Multiple Sclerosis Treatment Shown To Significantly …
Novartis Gains FDA Approval For Gilenya™, A Novel First-Line Multiple Sclerosis Treatment Shown To Significantly …
Today Novartis announced that the US Food and Drug Administration (FDA) approved the oral multiple sclerosis (MS) treatment Gilenya™ (fingolimod) 0.5 mg daily, a first-line treatment for relapsing forms of multiple sclerosis – the most common forms of the disease.
Read more on PharmaceuticalOnline
Categories: High Risk Breast Cancer Tags: Approval, FirstLine, gains, Gilenya™, Multiple, Novartis, novel, Sclerosis, Shown, significantly, Treatment
Novartis Vaccines Begins Shipment of Seasonal Influenza Vaccine Fluvirin(R) to U.S. Market to Help Protect Ahead of …
Novartis Vaccines Begins Shipment of Seasonal Influenza Vaccine Fluvirin(R) to U.S. Market to Help Protect Ahead of …
CAMBRIDGE, MA–(Marketwire – July 29, 2010) – Novartis Vaccines ( NYSE : NVS )
Read more on Marketwire
Categories: Breast Cancer Doctors Tags: Ahead, Begins, FluvirinR, help, Influenza, Market, Novartis, protect, Seasonal, Shipment, U.S., vaccine, Vaccines
Novartis, Myriad May Get Shield for Diagnostic Tests After High Court Case
Novartis, Myriad May Get Shield for Diagnostic Tests After High Court Case
Myriad Genetics Inc. , Genomic Health Inc. and the rest of the burgeoning industry for personalized medicine stand to gain from yesterday’s landmark U.S. Supreme Court decision on patenting business methods.
Read more on Bloomberg
Categories: Genetic Testing For Breast Cancer Tags: after, case, court, diagnostic, high, Myriad, Novartis, Shield, tests
Novartis, Myriad Get Boost After Court Patent Ruling
Novartis, Myriad Get Boost After Court Patent Ruling
Myriad Genetics Inc., Genomic Health Inc. and the rest of the burgeoning industry for personalized medicine stand to gain from yesterday’s landmark U.S. Supreme Court decision on patenting business methods.
Read more on BusinessWeek